27.02.2019, 20:10
Healthcare | Drugs - Generic | USA
Mylan stock spirals after earnings miss and weak guidance
...
Mylan reported fourth-quarter earnings of $51.2 million, or 10 cents a share. After taking out restructuring charges and other costs, the company claimed adjusted earnings of $1.30 a share, down from $1.43 a share in the fourth quarter of 2017. Analysts on average expected Mylan to report adjusted earnings of $1.35 a share, according to FactSet.
Revenue was $3.08 billion, down from $3.24 billion a year ago, but higher than the FactSet consensus of $3.06 billion. Mylan said sales in North America, which fell 18% to $874 million, were hurt by “restructuring and remediation activities” at its Morgantown manufacturing plant that were put into effect after the company received a warning letter in November from the Food and Drug Administration detailing manufacturing violations.
...
https://www.marketwatch.com/story/mylan-...2019-02-27
![[Bild: MYLc1dl1307.png]](https://finviz.com/publish/022719/MYLc1dl1307.png)
Mylan stock spirals after earnings miss and weak guidance
...
Mylan reported fourth-quarter earnings of $51.2 million, or 10 cents a share. After taking out restructuring charges and other costs, the company claimed adjusted earnings of $1.30 a share, down from $1.43 a share in the fourth quarter of 2017. Analysts on average expected Mylan to report adjusted earnings of $1.35 a share, according to FactSet.
Revenue was $3.08 billion, down from $3.24 billion a year ago, but higher than the FactSet consensus of $3.06 billion. Mylan said sales in North America, which fell 18% to $874 million, were hurt by “restructuring and remediation activities” at its Morgantown manufacturing plant that were put into effect after the company received a warning letter in November from the Food and Drug Administration detailing manufacturing violations.
...
https://www.marketwatch.com/story/mylan-...2019-02-27
![[Bild: MYLc1dl1540.png]](https://finviz.com/publish/050719/MYLc1dl1540.png)